Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.06 - $1.42 $53,954 - $72,278
-50,900 Reduced 68.97%
22,900 $25,000
Q4 2023

Feb 14, 2024

BUY
$1.0 - $1.5 $30,300 - $45,450
30,300 Added 69.66%
73,800 $98,000
Q3 2023

Nov 14, 2023

BUY
$1.03 - $1.85 $2,884 - $5,180
2,800 Added 6.88%
43,500 $46,000
Q2 2023

Aug 14, 2023

SELL
$1.04 - $1.64 $11,752 - $18,532
-11,300 Reduced 21.73%
40,700 $45,000
Q1 2023

May 15, 2023

SELL
$1.39 - $3.24 $129,964 - $302,940
-93,500 Reduced 64.26%
52,000 $76,000
Q4 2022

Feb 14, 2023

BUY
$2.32 - $3.68 $74,472 - $118,128
32,100 Added 28.31%
145,500 $366,000
Q3 2022

Nov 14, 2022

SELL
$2.87 - $7.01 $69,454 - $169,642
-24,200 Reduced 17.59%
113,400 $364,000

Others Institutions Holding CODX

About Co-Diagnostics, Inc.


  • Ticker CODX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 33,781,000
  • Market Cap $45.3M
  • Description
  • Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...
More about CODX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.